...
首页> 外文期刊>EBioMedicine >The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals
【24h】

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals

机译:miR-367-3p通过改变雄激素受体信号来提高索拉非尼的化学疗法疗效,以抑制肝细胞癌转移。

获取原文

摘要

The androgen receptor (AR) was found to suppress hepatocellular carcinoma (HCC) metastasis at late stages. Due to this discovery, we searched for some AR enhancers to increase the efficacy of Sorafenib chemotherapy, and identified the microRNA (miR)-367-3p, whose expression is positively correlated with AR expression in advanced HCC, as an HCC metastasis suppressor. Combining miR-367-3p with Sorafenib showed better efficacy to suppress HCC cell invasion in vitro and in vivo. Mechanism dissection revealed that miR-367-3p could increase AR expression via directly targeting the 3'UTR of MDM2 to decrease MDM2 protein expression. The resultant increase of AR expression might then promote the expression of FKBP5 and PHLPP, thus dephosphorylating and inactivating AKT and ERK, to suppress the HCC cell invasion. Interestingly, the suppression of pAKT by miR-367-3p could subsequently attenuate the phosphorylation of AR and MDM2, giving rise to additional enhancement of AR protein expression, effectively forming a positive feedback loop. Together, these results suggest that miR-367-3p may function as an AR enhancer to increase Sorafenib chemotherapy efficacy via altering the MDM2/AR/FKBP5/PHLPP/(pAKT and pERK) signals to better suppress HCC metastasis. Successful development of this newly combined chemotherapy in the future may help us to better suppress the HCC metastasis at late stages.
机译:发现雄激素受体(AR)在晚期可抑制肝细胞癌(HCC)转移。由于这一发现,我们搜索了一些AR增强剂以提高索拉非尼化疗的疗效,并鉴定了其microRNA(miR)-367-3p,其表达与晚期HCC中的AR表达呈正相关,作为HCC转移抑制剂。 miR-367-3p与索拉非尼的组合在体外和体内显示出更好的抑制HCC细胞侵袭的功效。机制解剖表明,miR-367-3p可以通过直接靶向MDM2的3'UTR来降低MDM2蛋白的表达,从而增加AR表达。因此,AR表达的增加可能会促进FKBP5和PHLPP的表达,从而使AKT和ERK磷酸化并失活,从而抑制HCC细胞侵袭。有趣的是,miR-367-3p对pAKT的抑制作用随后可减弱AR和MDM2的磷酸化,从而增强AR蛋白表达,从而有效地形成正反馈环。总之,这些结果表明,miR-367-3p可能通过增强MDM2 / AR / FKBP5 / PHLPP /(pAKT和pERK)信号来更好地抑制HCC转移,从而起到AR增强剂的作用,从而提高索拉非尼的化疗效果。将来这种新结合的化学疗法的成功开发可能有助于我们在晚期更好地抑制HCC转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号